keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium 90

keyword
https://www.readbyqxmd.com/read/29663029/yttrium-90-ibritumomab-tiuxetan-zevalin-followed-by-beam-z-beam-conditioning-regimen-and-autologous-stem-cell-transplantation-asct-in-relapsed-or-refractory-high-risk-b-cell-non-hodgkin-lymphoma-nhl-a-single-institution-italian-experience
#1
Chiara Ciochetto, Barbara Botto, Roberto Passera, Marilena Bellò, Giulia Benevolo, Carola Boccomini, Alessia Castellino, Annalisa Chiappella, Roberto Freilone, Maura Nicolosi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, Gianni Bisi, Umberto Vitolo
Chemo-refractory NHL has a very poor outcome; the addiction of RIT to salvage regiment pre ASCT had recently demonstrated promising results.We performed a retrospective sequential study to determine the feasibility of standard Zevalin with BEAM in high-risk relapse/refractory NHL. A matched cohort analysis with a group treated with standard BEAM without Zevalin was performed as secondary endpoint. Between October 2006 and January 2013, 37 NHL patients at high risk for progression or early (< 1 year) or multiple relapses were treated with Z-BEAM and ASCT after R-DHAP or R-ICE as salvage therapy...
April 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29651580/hepatotoxic-dose-thresholds-by-positron-emission-tomography-after-yttrium-90-radioembolization-of-liver-tumors-a-prospective-single-arm-observational-study
#2
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To define a threshold radiation dose to non-tumoral liver from 90 Y radioembolization that results in hepatic toxicity using pair-production PET. MATERIALS AND METHODS: This prospective single-arm study enrolled 35 patients undergoing radioembolization. A total of 34 patients (27 with HCC and 7 with liver metastases) were included in the final analysis. Of 27 patients with underlying cirrhosis, 22 and 5 patients were Child-Pugh A and B, respectively. Glass and resin microspheres were used in 32 (94%) and 2 (6%) patients, respectively...
April 12, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29616365/multi-institutional-quantitative-phantom-study-of-yttrium-90-pet-in-pet-mri-the-mr-quest-study
#3
Nichole M Maughan, Mootaz Eldib, David Faul, Maurizio Conti, Mattijs Elschot, Karin Knešaurek, Francesca Leek, David Townsend, Frank P DiFilippo, Kimberly Jackson, Stephan G Nekolla, Mathias Lukas, Michael Tapner, Parag J Parikh, Richard Laforest
BACKGROUND: Yttrium-90 (90 Y) radioembolization involves the intra-arterial delivery of radioactive microspheres to treat hepatic malignancies. Though this therapy involves careful pre-treatment planning and imaging, little is known about the precise location of the microspheres once they are administered. Recently, there has been growing interest post-radioembolization imaging using positron-emission tomography (PET) for quantitative dosimetry and identifying lesions that may benefit from additional salvage therapy...
April 4, 2018: EJNMMI Physics
https://www.readbyqxmd.com/read/29578364/treatment-of-hepatocellular-carcinoma-a-cost-analysis-of-yttrium-90-transarterial-radioembolization-versus-sorafenib
#4
Maria Grazia Lucà, Roberto Nani, Melanie Schranz, Massimo De Giorgio, Claudia Iegri, Roberto Agazzi, Francesco Sala, Giorgio Virotta, Donatella Sarti, Grazia Conte, Domenico Pinelli, Carlo Nicora, Michele Colledan, Sandro Sironi, Stefano Fagiuoli
AIM: The aim was to evaluate cost-effectiveness of yttrium-90 transarterial radioembolization (TARE) in comparison to sorafenib treatment. PATIENTS & METHODS: A single-center, retrospective, observational study was performed, 166 patients with intermediate-/advanced-stage hepatocellular carcinoma were treated with sorafenib and 19 with TARE. The patients out of the sorafenib group matching the inclusion criteria for TARE, were reassigned to a subgroup SOR3...
April 2018: Future Oncology
https://www.readbyqxmd.com/read/29559288/prospective-trial-using-internal-pair-production-positron-emission-tomography-to-establish-the-yttrium-90-radioembolization-dose-required-for-response-of-hepatocellular-carcinoma
#5
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To prospectively assess the threshold dose for objective response of hepatocellular carcinoma (HCC), using90 Y internal pair-production positron emission tomography (PET) to quantify the radiation dose delivered to hepatic tumors after radioembolization. METHODS AND MATERIALS: A prospective study was performed under institutional review board approval from 2012 to 2014. Thirty-five patients with primary and secondary liver tumors undergoing90 Y treatment were recruited...
February 9, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29523614/selective-internal-radiation-therapy-sirt-with-yttrium-90-microspheres-for-unresectable-intrahepatic-cholangiocarcinoma
#6
Vindya Abeysinghe, Siva Sundararajan, Luc Delriviere, Jonathan Tibballs
Unresectableintrahepaticcholangiocarcinoma has a very poor prognosis despite various treatment options. The case presented describes the diagnostic challenges of a young pregnant woman with unresectable cholangiocarcinoma. The current treatment options for cholangiocarcinoma have limited evidence and high recurrence rate. Given the young age of this patient, selective internal radiotherapy was trialled with traditional chemotherapy with a clinically significant result. This case highlights the delays when diagnosing cholangiocarcinoma in younger patients and the possibility of selective internal radiation therapy in combination with chemotherapy as a potential first-line treatment for a complete response in unresectable disease...
March 9, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29520178/imaging-evaluation-following-90-y-radioembolization-of-liver-tumors-what-radiologists-should-know
#7
REVIEW
Ijin Joo, Hyo-Cheol Kim, Gyoung Min Kim, Jin Chul Paeng
Radioembolization using beta-emitting yttrium-90 microspheres is being increasingly used for the treatment of primary and metastatic liver cancers. It is a form of intra-arterial brachytherapy which delivers intense radiation to liver tumors with little embolic effect; this mode of action results in unique post-treatment imaging findings. It is important to understand these imaging findings to avoid misinterpretation of tumor response and to determine further management of the disease. Herein, we discuss the current concepts for assessing tumor response, common post-treatment imaging features, and associated complications following radioembolization...
March 2018: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
https://www.readbyqxmd.com/read/29516130/radioembolisation-in-patients-with-hepatocellular-carcinoma-that-have-previously-received-liver-directed-therapies
#8
Bruno Sangro, Carlo Ludovico Maini, Giuseppe Maria Ettorre, Roberto Cianni, Rita Golfieri, Daniele Gasparini, Samer Ezziddin, Philipp M Paprottka, Francesco Fiore, Mark Van Buskirk, Jose Ignacio Bilbao, Rita Salvatori, Emanuela Giampalma, Onelio Geatti, Kai Wilhelm, Ralf Thorsten Hoffmann, Francesco Izzo, Mercedes Iñarrairaegui, Carlo Urigo, Alberta Cappelli, Alessandro Vit, Hojjat Ahmadzadehfar, Tobias Franz Jakobs, Rosa Sciuto, Giuseppe Pizzi, Secondo Lastoria
PURPOSE: Radioembolisation is part of the multimodal treatment of hepatocellular carcinoma (HCC) at specialist liver centres. This study analysed the impact of prior treatment on tolerability and survival following radioembolisation. METHODS: This was a retrospective analysis of 325 consecutive patients with a confirmed diagnosis of HCC, who received radioembolisation with yttrium-90 resin microspheres at eight European centres between September 2003 and December 2009...
March 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29498924/sirvenib-selective-internal-radiation-therapy-versus-sorafenib-in-asia-pacific-patients-with-hepatocellular-carcinoma
#9
Pierce K H Chow, Mihir Gandhi, Say-Beng Tan, Maung Win Khin, Ariunaa Khasbazar, Janus Ong, Su Pin Choo, Peng Chung Cheow, Chanisa Chotipanich, Kieron Lim, Laurentius A Lesmana, Tjakra W Manuaba, Boon Koon Yoong, Aloysius Raj, Chiong Soon Law, Ian H Y Cua, Rolley R Lobo, Catherine S C Teh, Yun Hwan Kim, Yun Won Jong, Ho-Seong Han, Si-Hyun Bae, Hyun-Ki Yoon, Rheun-Chuan Lee, Chien-Fu Hung, Cheng-Yuan Peng, Po-Chin Liang, Adam Bartlett, Kenneth Y Y Kok, Choon-Hua Thng, Albert Su-Chong Low, Anthony S W Goh, Kiang Hiong Tay, Richard H G Lo, Brian K P Goh, David C E Ng, Ganesh Lekurwale, Wei Ming Liew, Val Gebski, Kenneth S W Mak, Khee Chee Soo
Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (90 Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment...
March 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29496075/yttrium-90-radioembolization-for-unresectable-metastatic-neuroendocrine-liver-tumor-a-systematic-review
#10
REVIEW
Zhongzhi Jia, Weiping Wang
OBJECTIVE: To evaluate the value of yttrium-90 (90 Y) microspheres in the management of unresectable liver metastases secondary to neuroendocrine tumors (NETs). MATERIALS AND METHODS: PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the "gray" literature (Google Scholar) were searched for all studies related to90 Y therapy for unresectable liver metastases of NETs. RESULTS: A total of 11 studies and 7 abstracts involving 870 patients were included in the final analysis...
March 2018: European Journal of Radiology
https://www.readbyqxmd.com/read/29476021/updated-results-of-rituximab-pre-and-post-beam-with-or-without-90yttrium-ibritumomab-tiuxetan-during-autologous-transplant-for-diffuse-large-b-cell-lymphoma
#11
Jad Chahoud, Dawen Sui, William D Erwin, Alison M Gulbis, Martin Korbling, Mingzhi Zhang, Sairah Ahmed, Gheath Alatrash, Paolo Anderlini, Stefan O Ciurea, Betul Oran, Luis Fayad, Roland L Bassett, Elias Jabbour, L Jeffrey Medeiros, Homer A Macapinlac, Ken H Young, Issa F Khouri
PURPOSE: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (90YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). EXPERIMENTAL DESIGN: Patients were enrolled on three consecutive phase 2 clinical trials. Patients received two doses of rituximab (375 mg/m2 and 1000 mg/m2) during mobilization of stem cells, followed by 1000 mg/m2 on days +1 and +8 after ASCT with R-BEAM or 90YIT-R-BEAM (90YIT dose of 0...
February 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29471300/yttrium-90-ibritumomab-tiuxetan-zevalin%C3%A2-radioimmunotherapy-after-cytoreduction-with-eshap-chemotherapy-in-patients-with-relapsed-follicular-non-hodgkin-lymphoma-final-results-of-a-phase-ii-study
#12
Soham D Puvvada, José M Guillén-Rodríguez, Jessica Yan, Lora Inclán, Kara Heard, Xavier I Rivera, Faiz Anwer, Daruka Mahadevan, Jonathan H Schatz, Daniel O Persky
BACKGROUND: Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease after cytoreduction. METHODS: Patients with FL received 2 cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) every 28 days, followed by Zevalin 4-6 weeks later if there was no disease progression and bone marrow biopsy showed < 25% involvement...
February 22, 2018: Oncology
https://www.readbyqxmd.com/read/29468286/fibrolamellar-hepatocellular-carcinoma-treatment-with-yttrium-90-and-subsequent-surgical-resection
#13
Sebastian Mafeld, Jeremy French, Dina Tiniakos, Beate Haugk, Derek Manas, Peter Littler
We describe a 52-year-old female patient who presented with a 9.5-cm fibrolamellar hepatocellular carcinoma (FL-HCC). The patient was initially unsuitable for surgical resection and therefore underwent transarterial chemoembolization followed by selective internal radiation therapy (SIRT) with Yttrium-90 to downsize the tumour. Following SIRT, the tumour decreased in volume from 350 to 20 cm3 allowing curative (R0) resection with an extended left hepatectomy and reconstruction of IVC. This is the first reported case of FL-HCC treated with SIRT in which, due to the good SIRT response, the patient was downsized to allow curative resection...
February 21, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29468134/yttrium-90-microsphere-selective-internal-radiation-therapy-for-liver-metastases-following-systemic-chemotherapy-and-surgical-resection-for-metastatic-adrenocortical-carcinoma
#14
Mina S Makary, Lawrence S Krishner, Evan J Wuthrick, Mark P Bloomston, Joshua D Dowell
Adrenocortical carcinoma (ACC) is a rare malignancy with generally poor outcomes and limited treatment options. While surgical resection can be curative for early local disease, most patients present with advanced ACC owing to nonspecific symptoms. For those patients, treatment options include systemic chemotherapy and locoregional therapies including radiofrequency ablation and transarterial chemoembolization. We present the first reported case of utilizing yttrium-90 microsphere selective internal radiation therapy (SIRT) in combination with first line EDP-M (Etoposide, Doxorubicin, Cisplatin, Mitotane) chemotherapy and debulking surgical primary tumor resection for treatment of metastatic ACC...
February 10, 2018: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29464101/pneumatocele-during-sorafenib-therapy-first-report-of-an-unusual-complication
#15
Paloma Sangro, Idoia Bilbao, Nerea Fernández-Ros, Mercedes Iñarrairaegui, Javier Zulueta, J I Bilbao, Bruno Sangro
Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29448165/y90-radioembolization-dosimetry-using-a-simple-semi-quantitative-method-in-intrahepatic-cholangiocarcinoma-glass-versus-resin-microspheres
#16
Nariman Nezami, Nima Kokabi, Juan C Camacho, David M Schuster, Minzhi Xing, Hyun S Kim
INTRODUCTION: There are two different types of Y90 Microspheres, glass and resin, in the market for Y90 radioembolization (Y90-RE). This study aimed to investigate the dose of radiation delivered through glass vs. resin-based Y90-RE to intrahepatic cholangiocarcinoma (ICC). METHODS: In this retrospective study, 10 patients with ICC underwent Y90-RE, five underwent glass (Glass group) and other 5 resin (Resin group) microspheres. Technetium-99m macro-aggregated albumin (Tc-99m MAA) shunt study was performed two weeks before Y90-RE...
January 16, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29440463/immune-activation-underlies-a-sustained-clinical-response-to-yttrium-90-radioembolisation-in-hepatocellular-carcinoma
#17
Valerie Chew, Yun Hua Lee, Lu Pan, Nurul J M Nasir, Chun Jye Lim, Camillus Chua, Liyun Lai, Sharifah Nur Hazirah, Tony Kiat Hon Lim, Brian K P Goh, Alexander Chung, Richard H G Lo, David Ng, Rene L F Filarca, Salvatore Albani, Pierce K H Chow
OBJECTIVES: Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinoma and delays disease progression. The current study is designed to deeply interrogate the immunological impact of Y90-RE, which elicits a sustained therapeutic response. DESIGN: Time-of-flight mass cytometry and next-generation sequencing (NGS) were used to analyse the immune landscapes of tumour-infiltrating leucocytes (TILs), tumour tissues and peripheral blood mononuclear cells (PBMCs) at different time points before and after Y90-RE...
February 13, 2018: Gut
https://www.readbyqxmd.com/read/29435123/signature-of-survival-a-18-f-fdg-pet-based-whole-liver-radiomic-analysis-predicts-survival-after-90-y-tare-for-hepatocellular-carcinoma
#18
Paul Blanc-Durand, Axel Van Der Gucht, Mario Jreige, Marie Nicod-Lalonde, Marina Silva-Monteiro, John O Prior, Alban Denys, Adrien Depeursinge, Niklaus Schaefer
Purpose: To generate a predictive whole-liver radiomics scoring system for progression-free survival (PFS) and overall survival (OS) in patients undergoing transarterial radioembolization using Yttrium-90 ( 90 Y-TARE) for unresectable hepatocellular carcinoma (uHCC). Results: The generated pPET-RadScores were significantly correlated with survival for PFS (median of 11.4 mo [95% confidence interval CI: 6.3-16.5 mo] in low-risk group [PFS-pPET-RadScore < 0.09] vs...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29425829/assessment-and-optimization-of-liver-volume-before-major-hepatic-resection-current-guidelines-and-a-narrative-review
#19
REVIEW
Adeel S Khan, Sandra Garcia-Aroz, Mohammad A Ansari, Syed M Atiq, Michael Senter-Zapata, Kathryn Fowler, M B Doyle, W C Chapman
Post hepatectomy liver failure (PHLF) remains a significant cause of morbidity and mortality after major liver resection. Although the etiology of PHLF is multifactorial, an inadequate functional liver remnant (FLR) is felt to be the most important modifiable predictor of PHLF. Pre-operative evaluation of FLR function and volume is of paramount importance before proceeding with any major liver resection. Patients with inadequate or borderline FLR volume must be considered for volume optimization strategies such as portal vein embolization (PVE), two stage hepatectomy with portal vein ligation (PVL), Yttrium-90 radioembolization, and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)...
February 6, 2018: International Journal of Surgery
https://www.readbyqxmd.com/read/29406240/ibritumomab-tiuxetan-zevalin-and-elevated-serum-human-anti-murine-antibody-hama
#20
Sarbajit Mukherjee, Adanma Ayanambakkam, Sami Ibrahimi, Sarah Schmidt, Jennifer Holter Charkrabarty, Mohamad Khawandanah
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. It is FDA approved for treatment of relapsed low grade or follicular B-cell Non-Hodgkin's Lymphoma (NHL) or newly diagnosed follicular NHL following an initial response to first-line chemotherapy. Patients may develop Human Anti-Murine Antibodies (HAMA), following exposure to murine antibodies. There is a concern for development of hypersensitivity reactions with Ibritumomab, especially in patients with an elevated HAMA titer...
February 1, 2018: Hematology/oncology and Stem Cell Therapy
keyword
keyword
8545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"